

Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION
(use as many sheets as necessary)

Complete If Known


NOV 10 2002

TECH CENTER 1600/2900

Application Number 09/613,508
Filing Date July 10, 2000
First Named Inventor He et al.
Group Art Unit 1653
Examiner Name Bugaisky, G.
Attorney Docket Number PF140P1D1

Sheet	1	of	4	Attorney Docket Number	PF140P1D1	
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	09/913,293		ROSEN et al.	NOT PUBLISHED	pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS:103167, 179522, 187075, and 202317
	AB	09/913,292		ROSEN et al.	NOT PUBLISHED	pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NO:14507
	AC	5,552, 536		NICHOLSON et al.	09-03-96	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
[Signature]	AD		WO96/33268		MERCK & CO., INC. et al.	10-24-96		
	AE		EP 0 533 226		MERCK & CO., INC.	03-24-93		
	AF		CA 2075662		MERCK & CO., INC.	02-17-93		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	AG	GeneSeq Accession No. T66992 (08-05-97) IDUN PHARM., INC. et al., "Apototic protease Mch3-alpha cDNA"			
	AH	GeneSeq Accession No. T66970 (07-21-97) VERTEX PHARM., INC., "Cysteine protease CMH-1 cDNA"			
	AI	GeneSeq Accession No. T66993 (08-05-97) IDUN PHARM., INC., "Cysteine protease Mch3-beta cDNA"			
	AJ	GeneSeq Accession No. W15247 (07-21-97) VERTEX PHARM., INC., "Cysteine protease CMH-1"			
	AK	GeneSeq Accession No. W15262 (08-05-97) IDUN PHARM., INC., "Apototic protease Mch3-alpha"			
	AL	GeneSeq Accession No. W15263 (08-05-97) IDUN PHARM., INC., "Cysteine protease Mch3-beta"			
	AM	GenBank Accession No. U39613 (01-19-96) DUAN et al., "Human cysteine protease ICE-LAP3 mRNA"			
	AN	GenBank Accession No. U37448 (12-14-95) PERNANDES-ALNEMRI et al., "Human Mch3 isoform alpha (Mch3) mRNA"			
	AO	GenBank Accession No. U40281 (01-27-96) LIPPKE et al., "Human cysteine protease CMH-1 mRNA"			

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number

RECEIVED

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**
(use as many sheets as necessary)

Complete If Known NOV 19 2002

TECH CENTER 1600/2900

Sheet 2 of 4

Application Number	09/613,508
Filing Date	July 10, 2000
First Named Inventor	He et al.
Group Art Unit	1653
Examiner Name	Bugaisky, G.
Attorney Docket Number	PF140P1D1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AP	GenBank Accession No. U67319 (03-19-97) JUAN et al., "Human Lice 2 beta cysteine protease mRNA"	
	AQ	GenBank Accession No. U67320 (03-19-97) JUAN et al., "Human Lice 2 gamma cysteine protease mRNA"	
	AR	GenBank Accession No. U37449 (12-14-95) FERNANDES-ALNEMRI et al., "Human Mch3 isoform beta (Mch3) mRNA"	
	AS	GenBank Accession No. H91868 (11-29-95) HILLIER et al., "ys81a06.rl Soares retina N2b4HR Homo sapiens cDNA clone IMAGE:221170 5' similar to SP:A49429 A49429 CED-3+INTERLEUKIN-1 BETA-CONVERTING ENZYME HOMOLOG - CAENORHABDITIS ;, mRNA sequence"	
	AT	GeneSeq Accession No. V05471 (07-02-98) UNIV. MICHIGAN, "Nucleic acid encoding a protein designated YAMA"	
	AU	GeneSeq Accession No. T33567 (12-06-96) UNIV. MICHIGAN, "Pro-Yama cDNA"	
	AV	GeneSeq Accession No. V32608 (10-26-98) MERCK FROSST CANADA, INC., "Mutant human apopain (caspase-3) pro-enzyme cDNA"	
	AW	GeneSeq Accession No. V32615 (10-26-98) MERCK FROSST CANADA, INC., "Mutant human apopain (caspase-3) pro-enzyme cDNA"	
	AX	GeneSeq Accession No. W00677 (12-06-96) UNIV. MICHIGAN, "Pro-Yama"	
	AY	GeneSeq Accession No. W00372 (06-26-97) MERCK & CO., INC. et al., "Apopain CPP32beta proenzyme"	
	AZ	GeneSeq Accession No. W41688 (07-02-98) UNIV. MICHIGAN, "Amino acid sequence of a protein designated YAMA"	
	BA	GeneSeq Accession No. W16600 (06-26-97) MERCK & CO., INC. et al., "Apopain CPP32a proenzyme"	
	BB	GeneSeq Accession No. W48945 (10-26-98) MERCK FROSST CANADA, INC., "Mutant human apopain (caspase-3) C163S pro-enzyme"	
	BC	GeneSeq Accession No. W48937 (10-26-98) MERCK FROSST CANADA, INC., "Mutant human apopain (caspase-3) C163S pro-enzyme"	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

NOV 10 2002

TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION
(use as many sheets as necessary)

Complete If Known

Application Number	09/613,508
Filing Date	July 10, 2000
First Named Inventor	He et al.
Group Art Unit	1653
Examiner Name	Bugaisky, G.
Attorney Docket Number	PF140P1D1

Sheet 3 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³	Kind Code ⁴ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BD	GenBank Accession No. U26943 (08-29-95) TEWARI et al., "Human cysteine protease Yama mRNA"	
	BE	GenBank Accession No. U13737 (04-14-95) FERNANDES-ALNEMRI et al., "Human cysteine protease CPP32 isoform alpha mRNA"	
	BF	GenBank Accession No. U13738 (04-14-95) FERNANDES-ALNEMRI et al., "Human cysteine protease CPP32 isoform beta mRNA"	
	BG	GenBank Accession No. T10341 (06-07-94) SOARES et al., "seq1254 b4HB3MA Cot8-HAP-Ft Homo sapiens cDNA clone b4HB3MA-COT8-HAP-Ft280 5' similar to similar to Human Cysteine proteinase and to Mouse Interleukin 1-beta convertase, mRNA sequence"	
	BH	GenBank Accession No. H29199 (07-17-95) HILLIER et al., "ym31f1.1 Soares infant brain 1N1B Homo sapiens cDNA clone IMAGE:49729 5' similar to SP:A49429 A49429 CED-3=INTERLEUKIN-1 BETA-CONVERTING ENZYME HOMOLOG - CAENORHABDITIS ;, mRNA sequence"	
	BI	GenBank Accession No. N85243 (04-01-96) LIEW, C.C., "J2957F Human fetal heart, Lambda ZAP Express Homo sapiens cDNA clone J2957 5' similar to CYSTEINE PROTEASE CPP32, mRNA sequence"	
	BJ	CERRETTI et al., "Molecular Cloning of the Interleukin-1 β Converting Enzyme," <i>Science</i> , 256:97-100 (04-03-92).	
	BK	WALKER et al., "Crystal Structure of the Cysteine Protease Interleukin-1 β -Converting Enzyme: A (p20/p10) ₂ Homodimer," <i>Cell</i> , 78:343-352 (07-29-94), Cell Press.	
	BL	WANG et al., "Ich-1, an Ice/ced-3-Related Gene, Encodes Both Positive and Negative Regulators of Programmed Cell Death," <i>Cell</i> , 78:739-750 (09-09-94), Cell Press.	
	BM	HENKART, P., "ICE Family Proteases: Mediators of All Apoptotic Cell Death?," <i>Immunity</i> , 4:195-201 (03-96), Cell Press.	

Examiner

Date Considered

3/3/03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED

NOV 19 2002

Complete If Known TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION
(use as many sheets as necessary)

Sheet

4

of

4

Application Number

09/613,508

Filing Date

July 10, 2000

First Named Inventor

He et al.

Group Art Unit

1653

Examiner Name

Bugaisky, G.

Attorney Docket Number

PF140P1D1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ² Number ⁴ Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BN	KAMENS et al., "Identification and Characterization of ICH-2, a Novel Member of the Interleukin-1 β -converting Enzyme Family of Cysteine Proteases," <i>J. Biol. Chem.</i> , 270(25):15250-15256 (1995), The American Society for Biochemistry and Molecular Biology, Inc., U.S.A.	
	BO	MUNDAY et al., "Molecular Cloning and Pro-apoptotic Activity of ICE _{rel} II and ICE _{rel} III, Members of the ICE/CED-3 Family of Cysteine Proteases," <i>J. Biol. Chem.</i> , 270(26):15870-15876 (1995), The American Society for Biochemistry and Molecular Biology, Inc., U.S.A.	
	BP	TEWARI et al., "Yama/CPP32 β , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase," <i>Cell</i> , 81:801-809 (1995), Cell Press.	
	BQ	FAUCHEU et al., "A novel human protease similar to the interleukin-1 β converting enzyme induces apoptosis in transfected cells," <i>The EMBO Journal</i> , 14(9):1914-1922 (1995).	
	BR	GREENFEDER et al., "Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex," <i>J. Biol. Chem.</i> , 270(23):13757-13765 (06-09-95), The American Society for Biochemistry and Molecular Biology, Inc., U.S.A.	
	BS	MIURA et al., "Induction of Apoptosis in Fibroblasts by IL-1 β -Converting Enzyme, a Mammalian Homolog of the <i>C. elegans</i> Cell Death Gene <i>ced-3</i> ," <i>Cell</i> , 75:653-660 (11-19-93), Cell Press.	
	BT	FERNANDES-ALNEMRI et al., "CPP32, a Novel Human Apoptotic Protein with Homology to <i>Caenorhabditis elegans</i> Cell Death Protein Ced-3 and Mammalian Interleukin-1 β -converting Enzyme," <i>J. Biol. Chem.</i> , 269(49):30761-30764, (12-09-94), The American Society for Biochemistry and Molecular Biology, Inc., U.S.A.	
	BU	ELLIS et al., "Mechanisms and Functions of Cell Death," <i>Annu. Rev. Cell Biol.</i> , 7:663-698 (1991), Annual Reviews Inc.	
	BV	BARINAGA M., "Cell Suicide: By ICE, Not Fire," <i>Science</i> , 263:754-756 (02-11-94).	
	BW	CALLARD et al., "The Cytokine Facts Book," New York: Academic Press (1994), p. 31.	

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.